RedHill Biopharma (RDHL) Misses Q2 EPS by 4c

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $23.19 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• BTC Digital closes $7M private placement to build Georgia AI data center
• AeroVironment posts record quarterly revenue, issues FY2027 outlook